Cooper Companies, Inc. (The) (NYSE:COO)‘s stock had its “buy” rating restated by investment analysts at BMO Capital Markets in a research note issued to investors on Friday. They presently have a $272.00 price objective on the medical device company’s stock. BMO Capital Markets’ price target indicates a potential upside of 14.44% from the stock’s current price.

Other equities analysts have also recently issued research reports about the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $250.00 price target on shares of Cooper Companies, Inc. (The) in a research report on Thursday, July 6th. BidaskClub cut shares of Cooper Companies, Inc. (The) from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Robert W. Baird reaffirmed a “buy” rating and issued a $251.00 price target on shares of Cooper Companies, Inc. (The) in a research report on Thursday, August 24th. Cleveland Research reaffirmed a “buy” rating on shares of Cooper Companies, Inc. (The) in a research report on Tuesday, August 22nd. Finally, Zacks Investment Research raised shares of Cooper Companies, Inc. (The) from a “hold” rating to a “buy” rating and set a $277.00 price target on the stock in a research report on Tuesday, August 22nd. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Cooper Companies, Inc. (The) has an average rating of “Buy” and an average price target of $261.11.

Cooper Companies, Inc. (The) (NYSE:COO) last announced its quarterly earnings results on Thursday, August 31st. The medical device company reported $2.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.58 by $0.06. Cooper Companies, Inc. (The) had a net margin of 16.45% and a return on equity of 16.00%. The business had revenue of $556.00 million for the quarter, compared to analysts’ expectations of $552.32 million. During the same quarter last year, the firm earned $2.30 EPS. The firm’s revenue for the quarter was up 8.0% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/13/bmo-capital-markets-reiterates-buy-rating-for-cooper-companies-inc-the-coo.html.

In other Cooper Companies, Inc. (The) news, Director Gary S. Petersmeyer sold 3,977 shares of Cooper Companies, Inc. (The) stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $244.94, for a total transaction of $974,126.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.60% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of COO. Janus Henderson Group PLC lifted its position in shares of Cooper Companies, Inc. (The) by 558.5% during the 2nd quarter. Janus Henderson Group PLC now owns 2,175,791 shares of the medical device company’s stock worth $520,937,000 after buying an additional 1,845,368 shares in the last quarter. Pioneer Investment Management Inc. lifted its position in shares of Cooper Companies, Inc. (The) by 136.6% during the 2nd quarter. Pioneer Investment Management Inc. now owns 1,226,250 shares of the medical device company’s stock worth $293,589,000 after buying an additional 708,028 shares in the last quarter. Janus Capital Management LLC lifted its position in shares of Cooper Companies, Inc. (The) by 35.7% during the 1st quarter. Janus Capital Management LLC now owns 1,743,182 shares of the medical device company’s stock worth $348,441,000 after buying an additional 458,173 shares in the last quarter. Koch Industries Inc. bought a new position in shares of Cooper Companies, Inc. (The) during the 2nd quarter worth approximately $312,000. Finally, Voya Investment Management LLC lifted its position in shares of Cooper Companies, Inc. (The) by 973.4% during the 2nd quarter. Voya Investment Management LLC now owns 329,015 shares of the medical device company’s stock worth $78,773,000 after buying an additional 298,363 shares in the last quarter. 95.78% of the stock is currently owned by hedge funds and other institutional investors.

Cooper Companies, Inc. (The) Company Profile

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Analyst Recommendations for Cooper Companies, Inc. (The) (NYSE:COO)

Receive News & Stock Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related stocks with our FREE daily email newsletter.